A hope was supposed to come in 2019 after the Food and Drug Administration (FDA) approved Ruxolitinib (RUX), a JAK1/2 inhibitor, for therapy of SR-aGVHD in adult and pediatric patients > 12 years [4]. Approval was based on favourable results of REACH2 clinical trial in which RUX showed the advantage over other well-known immunosuppressive therapies. Promising response rate to RUX at day 28 was 62.3% when compared with 39.4% in control group (p < 0.001) [5].
Obviously Reach2 failed to demonstrate true response rates.
- Forums
- ASX - By Stock
- MSB
- banter and General Discussion
banter and General Discussion, page-11080
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.16 |
Change
0.038(3.33%) |
Mkt cap ! $1.307B |
Open | High | Low | Value | Volume |
$1.13 | $1.17 | $1.13 | $1.523M | 1.323M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 17405 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 30 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 34779 | 1.165 |
9 | 31968 | 1.160 |
6 | 33588 | 1.155 |
7 | 27885 | 1.150 |
4 | 30776 | 1.145 |
Price($) | Vol. | No. |
---|---|---|
1.175 | 47069 | 13 |
1.180 | 63070 | 11 |
1.185 | 22398 | 8 |
1.190 | 278219 | 8 |
1.195 | 107415 | 3 |
Last trade - 11.08am 30/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |